Personal Injury Law

The Makers of Premarin, Prempro, and Provera Hit With $2.75 Million Verdict

By Jeff Lowe, Esq.

The manufactures of hormone replacement drugs lost their second case regarding the allegations that their drugs Premarin, Prempro, and Provera caused breast cancer. A federal jury awarded $2.75 million in actual damages to a woman who alleged her breast cancer was caused by hormone replacement drugs, Bloomberg News reports.

The suit was filed against Wyeth and a unit of Pfizer. The verdict is the first federal-court defeat for the two companies that make menopause drugs.

The plaintiff, Donna Scroggins, took a combination of hormone replacement drugs for ten years to ease her menopause symptoms such as hot flashes, night sweats and mood swings. She eventually developed breast cancer and underwent a double mastectomy.

In 2002, the Women?s Health Initiative study found that women who took a combination of estrogen and progestin hormones to relieve menopause symptoms increased their risk of invasive breast cancer by 24 percent.

Upjohn, a Pfizer unit, manufactures the progestin drug Provera. Wyeth makes the estrogen drug Premarin and Prempro, a drug that combines estrogen and progestin.

The federal jury in Little Rock, Arkansas that handed down the award is not done with Scroggins? case. On March 3, jurors will hear evidence on whether the two companies handling of the drugs merits a punitive damages award.

The lawyers of The Lowe Law Firm are experienced in helping people injured by a dangerous prescription drug. We will seek compensation for past and future medical expenses, past and future wages, pain and suffering, disability and other damages. We also represent family members in wrongful death cases.

We offer a free initial consultation for victims of dangerous medications. If you cannot make it to our office, we will come to you at the hospital or your home.

Contact the lawyers at The Lowe Law Firm today by calling 877-678-3400.

Full post as published by Missouri Injury Lawyer Blog on February 26, 2008 (boomark / email).